APPLICATION
ANDA206996
TYPE
ANDA
ORIGINAL APPROVAL
2017-03-22
LATEST ACTION
2024-12-03
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription
Products
PIPERACILLIN AND TAZOBACTAMPrescription
PIPERACILLIN SODIUM EQ 3GM BASE/VIAL, TAZOBACTAM SODIUM EQ 375MG BASE/VIAL · INJECTABLE · INJECTION
PIPERACILLIN AND TAZOBACTAMPrescription
PIPERACILLIN SODIUM EQ 4GM BASE/VIAL, TAZOBACTAM SODIUM EQ 500MG BASE/VIAL · INJECTABLE · INJECTION
PIPERACILLIN AND TAZOBACTAMPrescription
PIPERACILLIN SODIUM EQ 2GM BASE/VIAL, TAZOBACTAM SODIUM EQ 250MG BASE/VIAL · INJECTABLE · INJECTION
Approval history
2024-12-03Labeling · Supplement 10 · standardAP
2024-05-01Labeling · Supplement 9 · standardAP
2024-04-09Labeling · Supplement 8 · standardAP
2021-12-22Labeling · Supplement 6 · standardAP
2017-03-22UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.